The EPO published patent application EP3236946A1 for porous particles by Lucideon Limited on April 15, 2026. The inventors are Philip Richard Jackson, Mark Cresswell, and Ian F. Campbell, with the application classified under pharmaceutical formulation codes A61K 9/14, A61K 9/16, A61K 9/20, and A61K 31/00. The patent designation extends across all European Patent Convention contracting states including Germany, France, the United Kingdom, Italy, Spain, and 25 others. Pharmaceutical manufacturers developing similar porous particle formulations should evaluate freedom-to-operate implications within the designated states.
